True or false: The initial expedited ADR report must identify the patient, the suspect product, the reporting source, and indicate that the event is serious and unexpected with a reasonable suspected causal relationship.

True or false: The initial expedited ADR report must identify the patient, the suspect product, the reporting source, and indicate that the event is serious and unexpected with a reasonable suspected causal relationship.

• A. False
• B. Only for fatal events
• C. Never required
• D. True

Answer: (D)

In expedited adverse reaction reporting, the focus is on quickly alerting regulators to SUSARs. The initial expedited report must identify the patient, the suspect product, and the reporting source, and it must indicate that the event is serious and unexpected with a reasonable suspected causal relationship. This combination ensures the regulator can assess risk promptly: who was involved, what drug might be responsible, who reported it, how severe it is, whether it’s not already expected in the product’s labeling, and that there is at least some plausible link to the drug. Reports of serious, unexpected, and drug-related events trigger expedited timelines and regulatory review, whereas not all serious events are SUSARs and not all SAD/SAEs require expedited reporting if they’re expected. Details can be updated later as more information becomes available.

In expedited adverse reaction reporting, the focus is on quickly alerting regulators to SUSARs. The initial expedited report must identify the patient, the suspect product, and the reporting source, and it must indicate that the event is serious and unexpected with a reasonable suspected causal relationship. This combination ensures the regulator can assess risk promptly: who was involved, what drug might be responsible, who reported it, how severe it is, whether it’s not already expected in the product’s labeling, and that there is at least some plausible link to the drug. Reports of serious, unexpected, and drug-related events trigger expedited timelines and regulatory review, whereas not all serious events are SUSARs and not all SAD/SAEs require expedited reporting if they’re expected. Details can be updated later as more information becomes available.